Short answer
Stoke Therapeutics, Inc. (STOK) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CEO Ian F. Smith awarded discretionary bonus of $697,125 for 2025 performance.
Stoke Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO Ian F. Smith awarded discretionary bonus of $697,125 for 2025 performance
- Bonus equals 100% of his target annual bonus, despite not participating in standard 2025 program
- Board scored corporate goals at 150% of target: signals strong 2025 clinical and financial execution
- Smith appointed interim CEO March 2025, elevated to permanent CEO October 2025: bonus covers full year contribution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stoke Therapeutics, Inc. 8-K filings
Get the next STOK 8-K as it lands
Follow STOK for push alerts, or ask the research agent what this filing means.